Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 936 trials

AMG 193 for Advanced Gastrointestinal and Pancreatic Cancers

We are testing AMG 193 combined with other therapies for patients with advanced gastrointestinal, biliary tract, or pancreatic cancers that have a specific genetic deletion. The goal is to see if this combination improves treatment outcomes.

Biliary and Pancreatic Cancer>2 yearsSafety phase (I)Oncology

Non-Small Cell Lung Cancer: U3-1402 Treatment

We are studying a new treatment called U3-1402 for individuals with non-small cell lung cancer. The goal is to see how well it works compared to current therapies.

Metastatic Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Solid Tumors: NECVAX-NEO1 with PD-1/PD-L1 Therapy

We are studying a new treatment, NECVAX-NEO1, for patients with solid tumors already on PD-1 or PD-L1 therapy. The trial aims to assess its safety and how well it may work in combination with existing treatments.

Advanced Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Solid Tumors: New Oral Anti-Tumor Treatment

We are testing a new oral medication for patients with solid tumors. The goal is to see if it works better than current treatments.

Advanced Solid TumorsSafety phase (I)Oncology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: LY4170156 Treatment

We are studying a new treatment called LY4170156 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to current options.

Solid Tumors>2 yearsSafety phase (I)Oncology

AMG 193 for Advanced Thoracic Tumors

We are studying the effects of AMG 193, alone and with other treatments, in patients with advanced thoracic tumors that have a specific genetic deletion. This research aims to find better treatment options for these patients.

Non-small Cell Lung CancerThoracic Tumors with Homozygous MTAP-deletionSafety phase (I)Oncology

Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases

We are studying a new treatment for people with active B-driven autoimmune diseases like lupus and scleroderma. The trial aims to evaluate its safety and initial effectiveness in managing these conditions.

Refractory Systemic Autoimmune Diseases3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Tafasitamab for Pediatric Acute B Lineage Leukemia

We are studying a new treatment for children with relapsed or refractory acute B lineage leukemia to see if it can help delay disease relapse and improve survival rates.

Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyPediatrics

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Acute Myeloid Leukemia: New Oral Drug for IDH1 Mutation

We are testing a new oral medication for patients with AML or other blood cancers that have an IDH1 mutation. The study aims to evaluate the safety and activity of this investigational drug.

Acute Myeloid Leukaemia>2 yearsSafety phase (I)HematologyOncology

Immunological Diseases: RAY121 Treatment

We are testing RAY121 for people with various immunological diseases to see if it can help manage their condition by inhibiting the immune response.

Bullous PemphigoidImmune-Mediated Necrotizing MyopathyDermatomyositis1-2 yearsSafety phase (I)DermatologyRheumatology

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Prostate Cancer: CC 1 Antibody Study

We are evaluating a new antibody treatment for men whose prostate cancer has returned. The study aims to assess its safety and early signs of effectiveness.

Recurrent Prostate Cancer>2 yearsSafety phase (I)OncologyUrology

Advanced Liver Cancer: CT 01 and Everolimus Study

We are investigating whether CT 01 is safe to use alone or with Everolimus for patients with inoperable advanced liver cancer. This study aims to understand the safety of these treatment options.

Liver Cancer3-6 monthsSafety phase (I)HepatologyOncology

Advanced Solid Tumors: KQB198 Treatment Study

We are investigating a new treatment called KQB198 for individuals with advanced solid tumors. The study aims to assess its safety and effectiveness, both alone and with other therapies.

Solid Tumour>2 yearsSafety phase (I)Oncology

Advanced Blood Cancers: KQB198 Treatment Study

We are investigating a new treatment called KQB198 for individuals with advanced hematologic malignancies. The study aims to assess its safety and effectiveness, both alone and with other therapies.

Advanced Blood Cancer>2 yearsSafety phase (I)HematologyOncology

HPV Vaccine: PANHPVAX

We are testing a new vaccine aimed at generating an immune response against HPV in healthy volunteers. The study will help us understand its safety and how well it is tolerated.

Healthy Volunteers for HPV VaccinationSafety phase (I)Infectious DiseasesOncology

Advanced Cancer: BI 1703880 with Ezabenlimab

We are testing how well different doses of BI 1703880 work with ezabenlimab in people with advanced solid tumors. This study aims to see how well these treatments are tolerated.

Advanced Solid Tumours>2 yearsSafety phase (I)Oncology

Fanconi Anaemia: Gene Therapy Study

We are evaluating the long-term safety and effects of a gene therapy using modified cells in patients with Fanconi Anaemia Subtype A. This study aims to understand how well the treatment works and its impact on blood health over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine